The non-cyclical FTSE 100 defensives I’d buy and hold forever

The financial crisis was no speed bump for these growing, high margin, non-cyclical FTSE 100 (INDEXFTSE: UKX) constituents.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a rough few years for some traditionally defensive sectors such as consumer goods firms and big grocers. Changing shopping habits and discounters have tested the long-held assumption by many investors that these sectors could reliably grow throughout the business cycle. But despite issues for some traditional defensive sectors, others are still trading as strongly as they ever have.

Profiting from data 

One is credit bureaux, which hoover up personal data and credit payment histories from hundreds of millions of people, synthesise the data and sell it on to financial services firms and the like that base credit acceptance decisions on the information. For market leader Experian (LSE: EXPN), this means steady revenue growth throughout the economic cycle as consumers apply for loans in recessions and boom times alike.

And the company isn’t just betting on steadily growing demand from its core UK and US credit services divisions to boost long-term profits. Rather, the group is expanding into growth regions such as Latin America and Asia where consumer use of credit is growing rapidly from a small base. In the quarter to December, organic growth from Latin American operations was 7% and in Asia it was 12%, which together with strong growth in the US saw group revenue rise 5% year-on-year on a constant currency basis.

Thanks to the incredibly high barriers to entry for competitors, Experian’s reams of data fetch a high price from lenders who have only two realistic competitors to consider. Last year this meant operating margins reached a whopping 24.7%. High cash flow is being used to acquire related business service companies in high-growth categories such as IT security that are already paying off.

On top of the non-cyclical nature of its business and very good growth opportunities, Experian also returns gobs of cash to shareholders. Last year this included $381m in dividends that equals a 2% yield, with an even bigger share buyback programme of $600m well on its way to completion this year. All of these positive characteristics mean Experian is pricey at 23.7 times forward earnings, but for a stable business with great long-term potential, I reckon this isn’t a ridiculous price to pay.

Modern day alchemy

Also on my list is Croda (LSE: CRDA), a speciality chemicals firm that grew sales and profits straight through the financial crisis as management steered the group towards selling more chemicals for consumer goods, rather than more cyclical industrial end uses.

This change in focus has proven a goldmine in recent years as its created immense sales opportunities, evened out earnings and helped boost margins. Last year, the group’s constant currency revenue grew 4.6% to £1.3bn, while adjusted operating profits increased by 6.9% to £332m.

For now, management uses the high and rising cash flow from operations to invest in its internal R&D process, acquire complementary businesses and push into other sectors such as life sciences. Like Experian, Croda isn’t cheap at 24 times forward earnings, but with good growth prospects, a rapidly growing 1.7% dividend yield, and non-cyclical characteristics, its still one great business I’d love to own in my retirement accounts.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any of the shares mentioned. The Motley Fool UK has recommended Experian. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »